JP2017526930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526930A5 JP2017526930A5 JP2017513509A JP2017513509A JP2017526930A5 JP 2017526930 A5 JP2017526930 A5 JP 2017526930A5 JP 2017513509 A JP2017513509 A JP 2017513509A JP 2017513509 A JP2017513509 A JP 2017513509A JP 2017526930 A5 JP2017526930 A5 JP 2017526930A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- binding protein
- rgma
- level
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048745P | 2014-09-10 | 2014-09-10 | |
| US62/048,745 | 2014-09-10 | ||
| PCT/EP2015/070603 WO2016038084A1 (en) | 2014-09-10 | 2015-09-09 | Rgma fragment based diagnostic assay |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526930A JP2017526930A (ja) | 2017-09-14 |
| JP2017526930A5 true JP2017526930A5 (enExample) | 2018-10-18 |
| JP6879905B2 JP6879905B2 (ja) | 2021-06-02 |
Family
ID=54064367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513509A Expired - Fee Related JP6879905B2 (ja) | 2014-09-10 | 2015-09-09 | ＲＧＭａ断片ベース診断アッセイ |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20160069907A1 (enExample) |
| EP (1) | EP3191847A1 (enExample) |
| JP (1) | JP6879905B2 (enExample) |
| CN (2) | CN113267630A (enExample) |
| AU (2) | AU2015314240A1 (enExample) |
| BR (1) | BR112017004883A2 (enExample) |
| CA (1) | CA2956814A1 (enExample) |
| MX (2) | MX385216B (enExample) |
| TW (2) | TW202119030A (enExample) |
| WO (1) | WO2016038084A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1973902A2 (en) * | 2005-12-05 | 2008-10-01 | Affinium Pharmaceuticals, Inc. | 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
| KR20120118002A (ko) * | 2009-12-08 | 2012-10-25 | 애보트 게엠베하 운트 콤파니 카게 | 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체 |
| US20210269535A1 (en) | 2018-07-19 | 2021-09-02 | The University Of Tokyo | Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham |
| CN118767130A (zh) * | 2020-01-15 | 2024-10-15 | 国立大学法人大阪大学 | 糖尿病性自主神经障碍的预防或治疗剂 |
| CN112402554B (zh) * | 2020-10-26 | 2022-03-01 | 中国中医科学院广安门医院 | 一种治疗脑白质病的中药组合物及其应用 |
| US12306192B2 (en) | 2021-02-08 | 2025-05-20 | Cedars-Sinai Medical Center | Method of detecting cognitive impairment |
| EP4374300A4 (en) * | 2021-07-23 | 2025-06-11 | Cedars-Sinai Medical Center | Methods and systems for the early detection of ocular and/or neurological conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE312349T1 (de) * | 1998-07-03 | 2005-12-15 | Innogenetics Nv | Differentielle diagnose von neurodegeneration |
| ES2390425T3 (es) * | 2000-12-22 | 2012-11-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Uso de moléculas de orientación repulsivas (RGM) y sus moduladores |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| KR20120118002A (ko) * | 2009-12-08 | 2012-10-25 | 애보트 게엠베하 운트 콤파니 카게 | 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체 |
| KR20170102378A (ko) * | 2009-12-09 | 2017-09-08 | 미쓰비시 타나베 파마 코퍼레이션 | Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법 |
| US8735546B2 (en) * | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2012047706A2 (en) * | 2010-10-06 | 2012-04-12 | Massachusetts Eye & Ear Infirmary | Methods for promotiing reinnervation of auditory hair cells |
| WO2012174666A1 (en) * | 2011-06-22 | 2012-12-27 | UNIVERSITé LAVAL | Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease |
| EP3369746A1 (en) | 2012-01-27 | 2018-09-05 | AbbVie Deutschland GmbH & Co KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
-
2015
- 2015-09-09 BR BR112017004883A patent/BR112017004883A2/pt not_active IP Right Cessation
- 2015-09-09 CA CA2956814A patent/CA2956814A1/en not_active Abandoned
- 2015-09-09 EP EP15759819.4A patent/EP3191847A1/en not_active Withdrawn
- 2015-09-09 CN CN202110521844.0A patent/CN113267630A/zh active Pending
- 2015-09-09 AU AU2015314240A patent/AU2015314240A1/en not_active Abandoned
- 2015-09-09 TW TW109124697A patent/TW202119030A/zh unknown
- 2015-09-09 TW TW104129821A patent/TW201617612A/zh unknown
- 2015-09-09 MX MX2017003063A patent/MX385216B/es unknown
- 2015-09-09 JP JP2017513509A patent/JP6879905B2/ja not_active Expired - Fee Related
- 2015-09-09 WO PCT/EP2015/070603 patent/WO2016038084A1/en not_active Ceased
- 2015-09-09 CN CN201580048412.5A patent/CN107076757A/zh active Pending
- 2015-09-10 US US14/850,185 patent/US20160069907A1/en not_active Abandoned
-
2017
- 2017-03-08 MX MX2021009528A patent/MX2021009528A/es unknown
-
2019
- 2019-09-04 US US16/560,632 patent/US20200241012A1/en not_active Abandoned
-
2021
- 2021-03-02 US US17/190,135 patent/US20220018855A1/en not_active Abandoned
-
2022
- 2022-01-12 AU AU2022200160A patent/AU2022200160A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Biofluid biomarkers of Alzheimer’s disease: progress, problems, and perspectives | |
| Sengillo et al. | Deficiency in Mural Vascular Cells Coincides with Blood–Brain Barrier Disruption in A lzheimer's Disease | |
| Whelan et al. | Developments in scalable strategies for detecting early markers of cognitive decline | |
| Gasparotto et al. | Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment | |
| Laird et al. | High mobility group box protein‐1 promotes cerebral edema after traumatic brain injury via activation of toll‐like receptor 4 | |
| Tenembaum | Acute disseminated encephalomyelitis | |
| Bashir et al. | Increased severity of the CHIMERA model induces acute vascular injury, sub-acute deficits in memory recall, and chronic white matter gliosis | |
| Kraker et al. | An update on optic neuritis | |
| Nuzzo et al. | Inflammatory mediators as biomarkers in brain disorders | |
| CN106461645A (zh) | 外伤性脑损伤和神经退行性生物标记物、方法和系统 | |
| Chen et al. | The influence of ageing in the cerebrospinal fluid concentrations of proteins that are derived from the choroid plexus, brain, and plasma | |
| JP2012523009A5 (enExample) | ||
| Shimizu et al. | Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier | |
| JP2024069651A (ja) | 神経障害のバイオマーカーとしてインフラマソームタンパク質を検出するための方法 | |
| JP2015508887A5 (enExample) | ||
| Sbriscia et al. | miR-132–3p is down-regulated in plasma and CD171+ extracellular vesicles isolated from patients with mild Alzheimer’s disease | |
| JP2009515183A5 (enExample) | ||
| JP2018523092A5 (enExample) | ||
| Montague et al. | Advancements in multiple sclerosis | |
| Rommer et al. | Elevated levels of carbonyl proteins in cerebrospinal fluid of patients with neurodegenerative diseases | |
| Meltzer et al. | Updates and controversies in the management of acute optic neuritis | |
| Drummond et al. | The use of localized proteomics to identify the drivers of Alzheimer's disease pathogenesis | |
| RU2019144031A (ru) | Способ диагностики или мониторинга функции почек или диагностики дисфункции почек | |
| Svenningsen et al. | Clinical biomarkers and noninvasive assessment | |
| US20230321189A1 (en) | Therapeutic agents, pharmaceutical compositions, and associated biomarkers based on trk-b |